Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.

Jose F Varona,Pedro Landete, Roger Paredes,Roberto Vates,Miguel Torralba,Pablo Guisado-Vasco,Lourdes Porras,Patricia Muñoz,Paloma Gijon,Julio Ancochea, Elena Saiz,Fernanda Meira,Jose M Jimeno,Jose A Lopez-Martin,Vicente Estrada

Frontiers in cellular and infection microbiology（2023）

Cited 0|Views27

No score

Abstract

In conclusion, plitidepsin has demonstrated a favorable long-term safety profile in adult patients hospitalized for COVID-19. With the constraints of a low sample size and a lack of control, the rate of post-COVID-19 complications after treatment with plitidepsin is in the low range of published reports. (ClinicalTrials.gov Identifier: NCT05121740; https://clinicaltrials.gov/ct2/show/NCT05121740).

Translated text

Key words

COVID-19,SARS-CoV-2,long COVID,plitidepsin,post-COVID-19 complications

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined